In re Progenity, Inc. Securities Litigation

District Court, S.D. California·Decided March 4, 2026·No. 3:20-cv-01683·Unknown

Opinion

IN RE PROGENITY, INC. Case No.: 3:20-cv-01683-RBM-AHG SECURITIES LITIGATION ORDER: (1) GRANTING LEAD PLAINTIFFS’ MOTION FOR FINAL APPROVAL OF CLASS ACTION SETTLEMENT AND PLAN OF ALLOCATION [Doc. 98]; AND (2) GRANTING LEAD COUNSEL’S MOTION FOR AN AWARD OF REIMBURSEMENT OF LITIGATION EXPENSES [Doc. 99]

Pending before the Court are Lead Plaintiffs Lin Shen, Lingjun Lin, and Fusheng Lin’s (“Plaintiffs”) Motion for Final Approval of Class Action Settlement and Plan of Allocation (“Final Approval Motion”) (Doc. 98) and Lead Counsel’s Motion for an Award of Attorneys’ Fees and Reimbursement of Litigation Expenses (“Fees Motion”) (Doc. 99). On February 23, 2026, the Court held a hearing on the pending Motions. For the reasons stated herein, Plaintiffs’ Final Approval Motion and Fees Motion are GRANTED. A. Factual Background On behalf of themselves and similarly situated investors, Plaintiffs assert claims for violations of Sections 11 and 15 of the Securities Act of 1933 (the “Securities Act”), 15 U.S.C. §§ 77k and 77o arising from Progenity Inc.’s (“Progenity”) June 2020 initial public offering (the “IPO”) against three groups of defendants (collectively, “Defendants”): (1) Progenity; (2) Harry Stylli, Eric d’Esparbes, Jeffrey Alter, John Bigalke, Jeffrey Ferrell, Brian L. Kotzin, Samuel Nussbaum, and Lynne Powell (“Individual Defendants”); and (3) Piper Sandler & Co., Wells Fargo Securities, LLC, Robert W. Baird & Co. Incorporated, Raymond James & Associates, Inc., and BTIG, LLC (“Underwriter Defendants,” and with Individual Defendants, the “Remaining Defendants”).1 (Doc. 91-1 at 9.)2 1. Parties Progenity is a biotechnology company based in San Diego, California that develops and commercializes molecular testing products and precision medicine applications, including “in vitro molecular tests designed to assist parents in making informed decisions related to family planning, pregnancy, and complex disease diagnosis.” (Doc. 64, Third Amended Class Action Complaint [“TAC”] at 7.) At the time of the IPO, Progenity’s two most successful products were its Innatal and Preparent tests, which screen for fetal chromosomal conditions and mutations that cause genetic diseases, respectively. (Id.) Individual Defendants were executives or directors of Progenity who signed, or authorized the signing of, the Registration Statement issued in connection with Progenity’s IPO, “reviewed and helped prepare the Registration Statement,” and “participated in the solicitation and sale of [Progenity’s] common stock to investors in the IPO for their own financial benefit and the financial benefit of Progenity.” (Id. at 18.)

1 The Court refers to Plaintiffs and the Remaining Defendants collectively as the “Parties.”

Underwriter Defendants are financial services companies that acted as underwriters for Progenity’s IPO. (Id. at 18–19; Doc. 91-1 at 9 n. 2.) The Underwriter Defendants collectively “sold more than 6.6 million Progenity shares in the IPO at $15 per share and shared $7 million in underwriting discounts and commissions.” (TAC [Doc. 64] at 19.) 2. Factual Allegations Plaintiffs allege that Defendants made materially misleading statements in the Registration Statement issued in connection with Progenity’s IPO by failing to disclose that: “(i) Progenity had overbilled government payors for its Preparent genetic tests; (ii) shortly before the IPO Progenity abandoned its key illegal marketing practice of waiving patient payment amounts; and (iii) at the time of the IPO Progenity suffered from negative trends in test volumes, test average selling prices, and revenue.” (Doc. 91-1 at 9–10.) B. Procedural History In 2020, two class actions were separately filed in this District on behalf of investors who purchased Progenity’s securities in connection with the IPO.3 On December 3, 2020, the Court consolidated the cases, appointed Plaintiffs as co-Lead Plaintiffs, and approved Glancy, Prongay, & Murray LLP as lead counsel (“Lead Counsel” or “GPM”). (Doc. 33.) The Court previously granted Defendants’ motion to dismiss the Amended Class Action Complaint (see Doc. 40) and their motion to dismiss the Second Amended Complaint (see Doc. 52), but allowed Plaintiffs leave to amend on both occasions. (Docs. 48, 63.) On February 3, 2023, Plaintiffs filed the operative TAC. (Doc. 64.) Defendants once again filed a motion to dismiss (Doc. 67), which the Court granted with prejudice and entered judgment. (Docs. 70–71.) Plaintiffs appealed the Court’s order dismissing the TAC on August 11, 2023. (Doc. 72.) On September 7, 2023, the Parties and Progenity participated in an assessment

3 The cases are captioned Soe v. Progenity, Inc., et al., Case No. 20-cv-01683-RBM-AHG, and Brickman Investments Inc. v. Progenity, Inc., et al., Case No. 3:20-cv-01795-RBM- conference with Circuit Mediator Robert S. Kaiser to explore settlement potential. (Doc. 91-1 at 12–13.) Although no settlement was reached during this conference, the Parties and Progenity continued to engage in settlement negotiations while briefing Plaintiffs’ appeal in the Ninth Circuit. (Id.) On March 11, 2024, the Parties and Progenity reached an agreement in principle to settle the action for $1 million on a class-wide basis. (Id.) On July 3, 2024, the Ninth Circuit granted Plaintiffs’ Motion for Stay of Appeal and Limited Remand (Appeal Doc. 34) and remanded the action to this Court for the limited purpose of conducting proceedings relating to the settlement. (Doc. 75.) Plaintiffs then filed their original motion for preliminary settlement approval on September 23, 2024. (Doc. 77.) On December 27, 2024, while Plaintiffs’ original motion was pending, Progenity filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code, which operated as an automatic stay of litigation against the debtor (see 11 U.S.C. § 362(a)). (Doc. 91-1 at 13 (citing In re: Biora Therapeutics, Inc., Case No. 24-12849 (Bankr. D. Del.), ECF No. 1).) The Parties assessed the impact of Progenity’s bankruptcy petition on the original settlement agreement and negotiated the instant Settlement Agreement to supersede it. (Id. at 13.) Plaintiffs withdrew their original preliminary approval motion on May 12, 2025. (Doc. 90.) On May 13, 2025, Plaintiffs filed a renewed Unopposed Motion for Preliminary Approval of Class Action Settlement (Doc. 91-1), the terms and conditions of which are set forth in the Settlement Agreement (Doc. 91-3).4 On October 23, 2025, the Court granted the Unopposed Motion for Preliminary Approval (“Preliminary Approval Order”). (Doc. 96.) Plaintiffs filed the Final Approval Motion and the Fees Motion on January 20, 2026. (Docs. 98–99.) Plaintiffs then filed a Reply in Further Support of the Final Approval Motion and the Fees Motion on February 17, 2026. (Doc. 101.)

Free access — add to your briefcase to read the full text and ask questions with AI

In re Progenity, Inc. Securities Litigation, (S.D. Cal. 2026).

In re Progenity, Inc. Securities Litigation (In re Progenity, Inc. Securities Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Missouri v. Jenkins Ex Rel. Agyei
491 U.S. 274 (Supreme Court, 1989)
In Re Bluetooth Headset Products Liability
654 F.3d 935 (Ninth Circuit, 2011)
Silber v. Mabon
18 F.3d 1449 (Ninth Circuit, 1994)
Staton v. Boeing Co.
327 F.3d 938 (Ninth Circuit, 2003)
In Re Media Vision Technology Securities Litigation
913 F. Supp. 1362 (N.D. California, 1996)
In Re Omnivision Technologies, Inc.
559 F. Supp. 2d 1036 (N.D. California, 2008)
Curran v. Camden National Corp.
497 F. Supp. 2d 18 (D. Maine, 2007)
Fahey v. Massachusetts Department of Revenue
779 F.3d 1 (First Circuit, 2015)
Robert Briseno v. Conagra Foods, Inc.
998 F.3d 1014 (Ninth Circuit, 2021)
Hanlon v. Chrysler Corp.
150 F.3d 1011 (Ninth Circuit, 1998)
Vizcaino v. Microsoft Corp.
290 F.3d 1043 (Ninth Circuit, 2002)
Stein v. Board of City of New York
792 F.2d 13 (Second Circuit, 1986)
Class v. City of Seattle
955 F.2d 1268 (Ninth Circuit, 1992)